Format

Send to

Choose Destination
Nat Microbiol. 2019 Jun 3. doi: 10.1038/s41564-019-0453-2. [Epub ahead of print]

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry.

Author information

1
IrsiCaixa AIDS Research Institute, Badalona, Spain.
2
Universitat Autònoma de Barcelona, Barcelona, Spain.
3
Protein Tools Unit and Department of Immunology and Oncology, Spanish National Center for Biotechnology, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
4
Department of Pathology, Hospital Universitari General de Catalunya-Grupo Quirón Salud, Barcelona, Spain.
5
Universitat Internacional de Catalunya, Barcelona, Spain.
6
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.
7
Otorhinolaryngology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
8
IrsiCaixa AIDS Research Institute, Badalona, Spain. jmpicado@irsicaixa.es.
9
University of Vic-Central University of Catalonia, Vic, Spain. jmpicado@irsicaixa.es.
10
Catalan Institution for Research and Advanced Studies, Barcelona, Spain. jmpicado@irsicaixa.es.
11
IrsiCaixa AIDS Research Institute, Badalona, Spain. nizquierdo@irsicaixa.es.
12
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain. nizquierdo@irsicaixa.es.

Abstract

Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

PMID:
31160823
DOI:
10.1038/s41564-019-0453-2

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center